Literature DB >> 16031860

The amended insulin to glucose ratio and diagnosis of insulinoma in dogs.

J C Thompson1, B R Jones, P C Hickson.   

Abstract

Amended insulin to glucose ratios were calculated from the concentrations of serum insulin and blood glucose measured concurrently during either a glucagon tolerance test or after feeding in healthy dogs. Values greater than 30 microU/mg which are supportive of a diagnosis of insulinoma were obtained at certain times during the test period. Amended insulin to glucose ratios calculated from serum insulin and blood glucose concentrations obtained during a glucagon tolerance test and an oral glucose tolerance test on a dog with an insulinoma were less than 30 microU/mg, or equivocal, at different times during the test period. This indicates that under some circumstances healthy dogs may have elevated amended insulin to glucose ratios, and dogs with insulinoma may have a normal amended insulin to glucose ratio. Care is essential for interpretation of amended insulin to glucose ratios, and a diagnosis of insulinoma using the ratio must be made in conjunction with appropriate clinical signs of hypoglycaemia.

Entities:  

Year:  1995        PMID: 16031860     DOI: 10.1080/00480169.1995.35900

Source DB:  PubMed          Journal:  N Z Vet J        ISSN: 0048-0169            Impact factor:   1.628


  3 in total

1.  Hypoglycemia in a dog.

Authors:  Nicole J Fernandez; Jason Barton; Tim Spotswood
Journal:  Can Vet J       Date:  2009-04       Impact factor: 1.008

Review 2.  Review of oncological emergencies in small animal patients.

Authors:  Katrina L Tumielewicz; Danielle Hudak; Jennifer Kim; David W Hunley; Lisa A Murphy
Journal:  Vet Med Sci       Date:  2019-03-21

3.  Incidence of postoperative complications and outcome of 48 dogs undergoing surgical management of insulinoma.

Authors:  Isaac Del Busto; Alexander J German; Elisabetta Treggiari; Giorgio Romanelli; Erin M O'Connell; Daniel J Batchelor; Paolo Silvestrini; Kevin Murtagh
Journal:  J Vet Intern Med       Date:  2020-03-25       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.